[Treatment of urosepsis].
Szabó
Krisztina
K
Semmelweis Egyetem, Altalános Orvostudományi Kar Urológiai Klinika Budapest Ulloi út 78/b 1082. szabkr@freemail.hu
D000890:Anti-Infective Agents / Q000627:therapeutic use*; D001786:Blood Glucose / Q000378:metabolism; D006801:Humans; D011486:Protein C / Q000627:therapeutic use; D011704:Pyelonephritis / Q000150:complications / Q000628:therapy; D011994:Recombinant Proteins / Q000627:therapeutic use; D051437:Renal Insufficiency / Q000209:etiology / Q000517:prevention & control; D012131:Respiratory Insufficiency / Q000209:etiology / Q000517:prevention & control; D012307:Risk Factors; D018805:Sepsis / Q000628:therapy; D014546:Urinary Catheterization / Q000009:adverse effects; D014552:Urinary Tract Infections / Q000150:complications / Q000175:diagnosis / Q000188:drug therapy / Q000209:etiology / Q000517:prevention & control / Q000628:therapy*; D020246:Venous Thrombosis / Q000209:etiology / Q000517:prevention & control
D000890:Anti-Infective Agents; D001786:Blood Glucose; D011486:Protein C; D011994:Recombinant Proteins; C421124:drotrecogin alfa activated